CasLoc logo
All Cases PTAB Litigations UPC Oppositions

CIPHER PHARMACEUTICALS, INC. v. WATSON LABORATORIES, INC.-FLORIDA

1:13-cv-06502

Overview

Case Number 1:13-cv-06502
Filing Date 2013-10-29
Status Terminated
Termination Date 2015-10-30
Court District Court, D. New Jersey (njd)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

ACTAVIS, INC. Operating Company

Represented By

9 Attorneys Listed

RANBAXY PHARMACEUTICALS, INC. Operating Company

Represented By

3 Attorneys Listed

Respondent

RANBAXY, INC. Operating Company

Represented By

3 Attorneys Listed

Counter Claimant

ANDRX CORP. Operating Company

Represented By

9 Attorneys Listed

ACTAVIS LABORATORIES FL, INC. Operating Company

Represented By

3 Attorneys Listed

Counter Defendant

GALEPHAR PHARMACEUTICAL RESEARCH, INC. Operating Company

Represented By

3 Attorneys Listed

CIPHER PHARMACEUTICALS, INC. Operating Company

Represented By

3 Attorneys Listed

Court & Judges

Court

District Court, D. New Jersey (njd)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 6 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (6): 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8367102
Pharmaceutical semi-solid composition of isotretinoin
Filed: 2007-08-22
Issued: 2013-02-05
Expired (Term Ended)
Expires: 2025-08-22

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

32

Dispositive

0

Granted

13

Denied

0

Pending / Review

17

Motions by Category

Procedural / Extension Motion 21 Claim Construction / Markman Filing 11

Key Dispositive Motions & Rulings

Procedural / Extension Motion Granted
ORDER granting 144 Motion for Leave to Appear Pro Hac Vice as to Ashley Borom, Esquire. Shall make a payment of $150.00 to the Clerk of the United States Distri...
Entry #145 • 2015-09-08 Document →
Procedural / Extension Motion Granted
MOTION for Leave to Appear Pro Hac Vice of Ashley Borom by CIPHER PHARMACEUTICALS, INC., GALEPHAR PHARMACEUTICAL RESEARCH, INC., RANBAXY PHARMACEUTICALS, INC., ...
Entry #144 • 2015-09-04 Document →
Procedural / Extension Motion Granted
ORDER granting 126 Motion for Leave to Appear Pro Hac Vice as to Daniel Forchheimer, Esquire. Shall make a payment of $150.00 to the Clerk of the United States ...
Entry #129 • 2015-07-21 Document →
Procedural / Extension Motion Granted
MOTION for Leave to Appear Pro Hac Vice for Daniel Forchheimer by CIPHER PHARMACEUTICALS, INC., GALEPHAR PHARMACEUTICAL RESEARCH, INC., RANBAXY PHARMACEUTICALS,...
Entry #126 • 2015-07-16 Document →
Procedural / Extension Motion Granted
ORDER granting 114 Motion for Leave to Appear Pro Hac Vice as to Rachel Echols, Esq. Shall make a payment of $150.00 to the Clerk of the United States District ...
Entry #116 • 2015-05-04 Document →
Claim Construction / Markman Filing Granted
MOTION to Seal Portions of Plaintiffs' Responsive Claim Construction Brief, Portions of the Rebuttal Declaration of Martyn C. Davies, Phd, and Exhibits 53-57 to...
Entry #115 • 2015-05-01 Document →

Docket Entries

(232 total)
Pleading / Complaint

COMPLAINT against ACTAVIS PHARMA, INC., ACTAVIS, INC., ANDRX CORP., WATSON LABORATORIES, INC.-FLORIDA ( Filing and Admin fee $ 400 receipt number NEW5320946), filed by GALEPHAR PHARMACEUTICAL RESEARCH, INC., RANBAXY PHARMACEUTICALS, INC., CIPHER PHARMACEUTICALS, INC., RANBAXY, INC.. (Attachments: # (1) Civil Cover Sheet)(dr, )

Entry #1 • 2013-10-29
1

Corporate Disclosure Statement by RANBAXY PHARMACEUTICALS, INC. identifying RANBAXY, INC. as Corporate Parent.. (dr, )

Entry #2 • 2013-10-29
1

Corporate Disclosure Statement by GALEPHAR PHARMACEUTICAL RESEARCH, INC. identifying NONE as Corporate Parent.. (dr, )

Entry #3 • 2013-10-29
1

Corporate Disclosure Statement by CIPHER PHARMACEUTICALS, INC. identifying NONE as Corporate Parent.. (dr, )

Entry #4 • 2013-10-29
1

NOTICE of Appearance by AMY MEGAN HANDLER on behalf of All Plaintiffs (HANDLER, AMY)

Entry #5 • 2013-11-01
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc